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E-mail: junfujii@tottori-u.ac.jpShiga toxin-producing Escherichia coli (STEC) causes hemor-
rhagic colitis, hemolytic uremic syndrome, and acute enceph-
alopathies that may lead to sudden death or severe neurologic
sequelae. Current treatments, including immunoglobulin G
(IgG) immunoadsorption, plasma exchange, steroid pulse
therapy, and the monoclonal antibody eculizumab, have
limited effects against the severe neurologic sequelae. Multili-
neage-differentiating stress-enduring (Muse) cells are endoge-
nous reparative non-tumorigenic stem cells that naturally
reside in the body and are currently under clinical trials for
regenerative medicine. When administered intravenously,
Musecells accumulate to the damaged tissue, where they exert
anti-inflammatory, anti-apoptotic, anti-fibrotic, and immu-
nomodulatory effects, and replace damaged cells by differen-
tiating into tissue-constituent cells. Here, severely
immunocompromised non-obese diabetic/severe combined
immunodeficiency (NOD-SCID) mice orally inoculated with
9  109 colony-forming units of STEC O111 and treated
48 h later with intravenous injection of 5  104 Muse cells ex-
hibited 100% survival and no severe after-effects of infection.
Suppression of granulocyte-colony-stimulating factor (G-
CSF) by RNAi abolished the beneficial effects of Muse cells,
leading to a 40% death and significant body weight loss, sug-
gesting the involvement of G-CSF in the beneficial effects of
Muse cells in STEC-infected mice. Thus, intravenous admin-
istration of Muse cells could be a candidate therapeutic
approach for preventing fatal encephalopathy after STEC
infection.100 Molecular Therapy Vol. 28 No 1 January 2020 ª 2019 The Author(
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Shiga toxin-producing Escherichia coli (STEC) is a causative agent of
hemorrhagic diarrhea, hemolytic uremic syndrome (HUS), and acute
encephalopathies, which occasionally lead to sudden death.1 Infected
individuals may develop serious neurologic complications, including
apnea, seizures, coma, cortical blindness, hemiparesis, and loss of
consciousness. Children who recover from HUS-related encephalop-
athies exhibit low IQ, poor academic achievement, and epilepsy.1
Current treatments for acute encephalopathy, including plasma
exchange, steroid pulse therapy, immunoglobulin G (IgG) immu-
noadsorption, and the monoclonal C5 antibody eculizumab, have
limited effects.2
The main Shiga toxins (Stxs) produced by STEC, Stx1a and Stx2a,
comprise one A and five B subunit proteins.3 The Stxs-B subunit
binds with high affinity to globotriaosylceramide Gb3 (CD77) on
the plasma membrane of some eukaryotic cells,4 which is upregulated
by lipopolysaccharide (LPS), tumor necrosis factor-a, and inter-
leukin-1b.5,6 The Stxs-B subunit is retrogradely transported from
the cell membrane to the endoplasmic reticulum (ER), and only the
Stxs-A subunit enters the cytosol.7 The Stxs-A subunit removess).
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgadenine-4324 in 28S RNA of the 60S ribosomal subunit by N-glyco-
sidase activity,8 rendering ribosomes inactive for protein synthesis.9
Once Stxs translocate across the intestinal tract, they bind to neutro-
phils, monocytes, platelets, and other leukocytes circulating in the
bloodstream and release microvesicles containing the toxins.10 Stxs
target glomerular endothelial cells, which is the key event in
HUS-related acute renal failure, and directly bind to neurons and
endothelial cells in the CNS, leading to blood-brain barrier (BBB)
damage and acute encephalopathy.11–13
We previously generated a mouse model of acute encephalopathy by
oral inoculation with Stx2c-producing E. coli O157:H– (strain
E32511).11 This model exhibits apoptosis associated with caspase-3
activation in neurons in the anterior horn of the spinal cord and
the reticular formation of the medulla oblongata, as well as in brain
microvascular endothelial cells.12 Signs of infection in our mouse
model resemble features of human acute encephalopathy,14 such as
tremor, paralysis of the lower extremities, and spinal defects.12 Intra-
cerebroventricular administration of Stx2a induces reactive astrocytes
with high expression of glial fibrillary acidic protein (GFAP) along-
side apoptotic neurons in the anterior horn of the spinal cord, retic-
ular formation of the medulla oblongata, and brain microvascular
endothelial cells.15 Reactive astrocytes aggressively produce tumor
necrosis factor-a and nitric oxide, and exhibit polymorphonuclear
neutrophil chemoattractant activity,16 which affect the permeability
and integrity of brain microvascular endothelial cells, thereby impair-
ing BBB function.17
A novel non-tumorigenic endogenous pluripotent stem cell type, the
multi-lineage differentiating stress-enduring (Muse) cell, was re-
ported in 2010 by Kuroda et al.18 Muse cells are identified as cells
positive for the pluripotency surface marker stage-specific embryonic
antigen (SSEA)-3, and can be collected from the bone marrow, pe-
ripheral blood, and organ connective tissues. They are also available
as several percent of cultured fibroblasts and mesenchymal stem cells
(MSCs).19 They have low telomerase activity and are non-tumori-
genic, consistent with the fact that they reside in normal adult
tissues.18 Muse cells have several unique characteristics that might
be beneficial for the treatment of STEC-induced acute encephalopa-
thy. First, intravenously injected Muse cells specifically home to the
site of damage mainly via sphingosine-1-phosphate signals that are
produced by damaged cells and act through their receptors, which
are expressed on Muse cells.20 Second, homed Muse cells exert
anti-inflammatory, anti-apoptotic, anti-fibrotic, immunomodulatory,
and paracrine protection effects, which are expected to be therapeutic
for STEC-induced encephalopathy.20–24 They also replace damaged/
apoptotic cells by spontaneous differentiation into tissue-constituent
cells.20–24 Third, allografted and xenografted Muse cells escape host
immunologic attack, successfully home to the damaged site, and
remain in the tissue as tissue-constituent cells for longer than
6 months in allografts and 2 months in xenografts without need
for immunosuppressants.20,23 The ability of Muse cells to avoid
host immunologic attack may be explained, at least in part, by their
expression of histocompatibility leukocyte antigen G (HLA-G), ahistocompatibility antigen that mediates immune tolerance.25 Fourth,
Muse cells are easily accessible from commercially available MSCs
and fibroblasts,26,27 making them feasible for clinical application.
Clinical trials usingMuse cells to target four diseases, including stroke
and spinal cord injury, were initiated in 2018.25 All of the clinical trials
are based on intravenous injection of donor-derived Muse cells
without HLA matching or long-term immunosuppressant treatment.
Fifth, Muse cells tolerate stress by actively secreting prosurvival
factors such as 14-3-3 proteins and serpin, which play a key role in
regulating the cellular response to DNA damage.28,29 Muse cells are
thus expected to tolerate the microenvironment of STEC-induced
encephalopathy, which contains strong stress factors derived from
damaged neurons and glial cells, brain edema, inflammation, and
impaired BBB function.
The ready availability of allogeneic Muse cells and the simplicity of
intravenous administration are two important considerations for
exploring the beneficial effects of Muse cells against STEC-induced
encephalopathy. Here, we investigated the effectiveness of intrave-
nous injection of human Muse cells on encephalopathy caused by
oral STEC infection in mice and the main factors involved in the
beneficial effects.
RESULTS
Sensitivity of Crl:CD1 (ICR) and Non-obese Diabetic/Severe
Combined Immunodeficiency (NOD-SCID) Mice to STEC O111
and O157
Following the protocol (Figure S1A), we found that among the four
STEC strains, E32511 and O111 exhibited higher toxicity and were
therefore selected for the present study. All of the mice infected with
O157-Sakai and O157 Tokyo survived for 2 weeks, whereas 60% of
ICR mice infected with O111 survived for 2 weeks. All of the mice
infected with E32511 died within 144 h of infection (Figure S1B).
Next, we investigated the minimum dose of E32511 and O111
required to kill all NOD-SCID mice. None of the NOD-SCID
mice injected with 1  109 colony-forming unit (CFU) of E32511
and O111 died (100% survival; data not shown), whereas all mice
inoculated with 1  1010 CFU E32511 and O111 died within
108 h (Figure S1C). On the basis of these results, we used NOD-
SCID mice inoculated with 1  1010 CFU of E32511 and/or O111
to investigate the effectiveness of treatment with human Muse cells.
Distribution of Intravenously InjectedMuse and Non-Muse Cells
in E32511/O111-Infected NOD-SCID Mice
Human Muse cells were collected from human bone marrow-derived
mesenchymal stem cells (BM-MSCs) as SSEA-3-positive cells by cell
sorting, as previously described.18 Human “non-Muse cells,” i.e., cells
other than Muse cells in the BM-MSCs, were collected as SSEA-3-
negative cells.18 Previous studies demonstrated that intravenous
administration of 5  104 and 2 104 human Muse cells into mouse
liver damage30 and chronic kidney disease models,23 respectively, has
therapeutic effects, and local administration of 3  104 human Muse
cells in a rat stroke model provides structural and functional
recovery.31 Therefore, we considered 5  104 Muse/non-Muse cellsMolecular Therapy Vol. 28 No 1 January 2020 101
Figure 1. In VivoDynamics of Intravenously Injected
Muse and Non-Muse Cells, and Evaluation of the
Administration Method in E32511/O111-Infected
NOD-SCID Mice
(A) Experimental protocol for in vivo dynamics of Muse/
non-Muse cells after intravenous injection. (B) Mice were
orally inoculated with 1 1010 CFU of E32511 and O111.
After 24 or 48 h, nano-Lantern-labeledMuse or non-Muse
cells were intravenously injected into the tail vein. Mouse
whole bodies were observed by an in vivo imaging sys-
tem. (C) Experimental protocol for two groups of Muse cell
injection. (D and E) Survival rate (D) and change in body
weight (E) are shown. NOD-SCID mice infected with 1 
1010 CFU of O111 were divided into two groups: one
group (group 1) received an intravenous injection of 2.5 
104 Muse cells at two time points (24 and 48 h) and the
other group (group 2) received an intravenous injection of
5 104 Muse cells once at 48 h. Control animals received
an intravenous injection of PBS at 48 h after O111 infec-
tion. Although the total number of Muse cells injected was
the same in the two groups, all group 2 mice survived for
132 h (red line), whereas mice in group 1 (green line) and
the PBS (black line) group began to die at 96 and 120 h
with only 40% and 20% survival, respectively, at 132 h (D).
The next day (156 h), however, the survival rate of mice in
group 2 decreased to 40% (D). Body weight did not differ
significantly between groups 1 and 2 at 48–96 h (E). Mice
that survived in group 1 and the PBS group gained weight
compared with mice in group 2 at 132 h, probably
because the surviving mice in these groups were health-
ier. Of the five mice, only one mouse in the PBS group and
two mice in group 1 survived at 132 h. These findings
suggest that a single intravenous injection of 5  104
Muse cells at 48 h was more effective than an intravenous
injection of 2.5  104 Muse cells twice at 24 and 48 h,
even though the total injected Muse cell number was the
same. ns, not significant.
Molecular Therapyto be within the effective range for this experiment and injected this
amount into infected NOD-SCID mice for the present investigation.
The protocol for the in vivo imaging system (IVIS) used to evaluate
the in vivo dynamics of intravenously administered Muse and non-
Muse cells is shown in Figure 1A. Mice were orally inoculated with
1 1010 CFUof E32511 or O111. At 24 or 48 h after oral STEC inoc-
ulation, 5  104 nano-Lantern-labeled human-Muse or non-Muse
cells were injected into the tail vein and analyzed by the in vivo im-
aging system (Figure 1A). Both Muse and non-Muse cell injection at
24 h after infection produced almost no detectable luminescence
except in the tails and heads of the E32511- and O111-infected
mice, whereas injection of Muse cells at 48 h after infection pro-
duced detectable luminescence, particularly in regions correspond-102 Molecular Therapy Vol. 28 No 1 January 2020ing to the brain and spinal cord in the E32511-
and O111-infected mice. Injection of non-
Muse cells into E32511- and O111-infected
mice at 48 h produced less detectable signal
(Figure 1B). Luminescence was lightly detectedin the kidneys in theMuse group of E32511-infected mice injected at
48 h after infection (Figure 1B). These findings suggested that Muse
cells administered intravenously at 48 h after infection distributed
more broadly in the body than non-Muse cells administered at
24 h after infection.
We next compared the efficacy of one intravenous injection of 5 104
Muse cells at 48 h after infection with that of two intravenous injec-
tions of 2.5  104 cells, one at 24 h and one at 48 h, in O111-infected
NOD-SCID mice (Figure 1C). On the basis of the survival rate up to
132 h after the O111 inoculation, one injection of 5  104 Muse cells
administered 48 h after infection was more effective than two divided
injections of 2.5  104 Muse cells administered at 24 and 48 h after
infection (Figure 1D).
Figure 2. Effect of Intravenously Injected Muse Cells on Survival and Body Weight of NOD-SCID Mice Infected with E32511 or O111
(A) Experimental protocol for evaluating Muse/non-Muse cell injection on survival and change in body weight. (B and C) For E32511, 1  1010 CFU E32511 was orally
inoculated, and survival rate (B) and body weight (C) were observed after intravenous injection of 5 104 Muse/non-Muse cells. (D–G) For O111, 1 1010 CFU of O111 was
orally inoculated, and survival rate (D and F) and body weight (E and G) were observed after intravenous injection of either 3  104 or 5  104 Muse/non-Muse cells,
respectively. Mice in the control group were injected with the same volume of PBS. Statistical analysis was performed by the log rank test (Mantel-Cox) for survival curves or
post hoc tests (Scheffe’s and Tukey’s) for the change in body weight. *p < 0.05. ns, not significant.
www.moleculartherapy.orgEffect of Intravenously InjectedMuse Cells on Survival and Body
Weight in NOD-SCID Mice Infected with E32511 or O111
Based on the above findings, 5  104 Muse/non-Muse cells were
administered intravenously to NOD-SCID mice (14- to 18-g fe-
males) at 48 h after E32511 and O111 infection (Figure 2A).
The control group was injected intravenously with the PBS in the
same volume as that used for the Muse and non-Muse injections
and at the same time point.
In E32511-infected NOD-SCID mice, survival was significantly
longer in the Muse group compared with the non-Muse and controlgroups (p < 0.05; Figure 2B). A general linear model of repeated
measures with Scheffe’s and Tukey’s post hoc tests revealed that
body weight was significantly greater in the Muse group compared
with the non-Muse and control groups until the first mouse died
in the experiment, i.e., 60–84 h after infection (p < 0.05;
Figure 2C).
In O111-infected NOD-SCID mice, dose dependency was evaluated
by injecting 3  104 or 5  104 Muse/non-Muse cells. In O111-
infected NOD-SCID mice injected with 3  104 Muse cells, survival
was increased compared with that in the non-Muse and controlMolecular Therapy Vol. 28 No 1 January 2020 103
Figure 3. Distribution of Human Muse Cells in the
O111-Inoculated Mouse Brain at 3 Weeks and
3 Months after Inoculation
(A) Brains in the Muse group. The region indicated by the
white rectangle indicates an area in which COX IV+-human
Muse cells were detected. (B–D) Enlarged images of areas
indicated by the white rectangles in (A). The distribution of
human Muse cells, recognized as COX IV+ (red), and b3-
tubulin (green), pan-specific to both human and mouse, is
shown. (B) No COX IV immunoreactivity (engrafted white
cells) was observed in the reticular formation of the me-
dulla oblongata before injection of Muse cells as a control
(0 h). (C) At 3 weeks after O111 infection, COX IV immu-
noreactivity was observed in mice injected with human
Muse cells in the reticular formation of the medulla ob-
longata. (D) At 3 months after O111 infection, COX IV+
humanMuse cells were detected in the reticular formation
of the medulla oblongata. Scale bars: 50 mm. (E and F)
High-magnification images of areas from (C) and (D),
respectively. Especially, (F) is shown as 3D image to
detect yellow signal, the overlap of red and green signals.
Cells that were double positive for COX IV (red cells)
and b3-tubulin (green cells) indicated neuronal marker
expression in engrafted Muse cells. Scale bars: 50 mm.
(G and H) 3D images of (E) and (F), respectively, are
shown.
Molecular Therapygroups (p < 0.05; Figure 2D). Body weight, however, did not differ
significantly among the three groups (Figure 2E). In O111-infected
NOD-SCID mice injected with 5  104 Muse cells, survival was
40% at 132 h, whereas survival in the non-Muse and control groups
was 0% at 108 h (Figure 2F). Furthermore, body weight was signifi-
cantly greater in the Muse group than in the other two groups from
48 to 96 h (p < 0.05; Figure 2G).
Notably, several mice in theMuse group injected with 5 104 cells sur-
vived more than 132 h. Among the three repeated experiments shown
in Figure 2F (n = 5/experiment), one-third of the total (5/15) mice sur-
vived for 3 weeks (Figure 2F, 3 weeks). Twomice were killed at 3 weeks
for immunohistochemical analysis, and the remaining three mice were
followed further. All of them survived for up to 3 months and were104 Molecular Therapy Vol. 28 No 1 January 2020killed at this time point for immunohistochem-
ical analysis (Figure 2F, 3 months).
Distribution of Human Muse Cells in the
Mouse Brain at 3 Weeks or 3 Months after
the O111 Inoculation
We investigated the distribution of Muse cells in
the brains of the mice surviving 3 weeks and
3 months. These long-term surviving mice ex-
hibited noweight loss, spinal deformity, or flaccid
paralysis of the extremities (data not shown).
Because the Muse cells used in this study are
human cells, they can be identified using the
anti-human cytochrome c oxidase subunit 4(COX IV) antibody, which specifically labels human cells, in mouse
brain tissue. The brains of non-infected mice without any cell injec-
tion at 48 h were used as a negative control (0 h). Human Muse cells
positive for COX IV (COX IV+ human Muse cells) were detected in
the reticular formation of the medulla oblongata (Figures 3C and
3D). We also confirmed the distribution of Muse/non-Muse cells in
E32511-infected NOD-SCID mouse brain using the anti-human
mitochondria antibody with secondary anti-mouse IgG antibody
conjugated with Alexa Fluor 488. Muse cells were integrated around
the pons and medulla at 96 h, whereas non-Muse cells were scarcely
detected in the brain (Figure S2C).
The majority of the COX IV+ human Muse cells did not express
CD31, amarker for endothelial cells, or GFAP, amarker for astrocytes
Figure 4. GFAP+-Reactive Astrocytes in the Patient Brain of Autopsy Cases Infected with O111 and O157
(A) An autopsy case as a control (43-year-old man). Scale bar: 5 cm. Left and right specimen panels show H&E staining and glial fibrillary acidic protein (GFAP) immuno-
histochemistry of paraffin-embedded sections (immunohistochemistry) for astrocyte staining, respectively (scale bar: 50 mm). (B) An autopsy case of anO111-infected patient
(43-year-old woman). Scale bars: 5 cm. Areas were divided into three regions, P1, P2, and P3. From one to seven high-magnification images are shown for each white box in
P1–P3. P1 includes the cerebrum tectorium. P2 and P3 include the basal ganglia, thalamus, hippocampus, and temporal lobe white matter. In each area, left and right
(legend continued on next page)
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Figure 5. Engraftment of Intravenously InjectedMuse
Cells into O111-Infected NOD-SCID Mouse Brains
and Rapid Suppression of Reactive Astrocytes
(A) Experimental procedure. Mice were divided into two
groups: 5  104 Muse/non-Muse cells were intravenously
injected into the mice at 24 (24-h group) and 48 h (48-h
group) after inoculation with 1 1010 CFU of O111. Mice at
0 h after inoculation were used as the control. (B) Histologic
analysis for detecting engrafted human Muse/non-Muse
cells by human cytochrome c oxidase (COX IV) and reactive
astrocytes byGFAP. Box shows the region analyzed, which
corresponded to the reticular formation of the medulla ob-
longata. (B-2) Low-magnification images of the distribution
ofMuseandnon-Musecells in eachgroup. Injectedcells are
indicated by the light blue signal detected by immunohis-
tochemistry with tyramide signal amplification (mIHC) plus
cyanine 3/fluorescein-second antibody conjugate with BZ
analyzer. Inset in the Muse 48 h is a high-magnification
image of the area indicated by the white box. (B-3) Low-
magnification image of COX IV+ cells in the reticular forma-
tion of the medulla oblongata, and white boxes in B-3 are
enlarged in B-4. (B-5) Low-magnification image of GFAP+
cells in the reticular formation of themedulla oblongata, and
black boxes in (B-5) are enlarged in (B-6). Scale bars:
200mm(B-2, B-3, andB-5); 50mm(B-4andB-6).Graphsof
total area of Muse/non-Muse cells/mm2 (green bar), total
number of Muse/non-Muse cells (blue bar), total area of
GFAP+ reactive astrocyte/mm2 (redbar), and total number of
GFAP+ reactive astrocytes (yellow bar) are shown.
Molecular Therapyand reactive astrocytes (Figure S3). Muse cells expressing the
neuronal cell marker b3-tubulin, however, were observed in mice
that survived at 3 weeks and 3 months (Figures 3C–3G). These b3-
tubulin+/COX IV+ cells exhibited a neuron-like morphology with
nerve fiber-like processes in the 3-month-surviving mouse brain
(Figure 3H).specimen panels showH&E staining and GFAP immunohistochemistry, respectively (scale bars: 50 mm). (C) Orient
ganglia are shown in the blue box (O157 Tokyo patients), hippocampus in the green box, pons in the red box, med
box. Following the outbreak of STEC O157:H7 in 2016, autopsies were performed. In the basal ganglia, O157 pa
(89-year-old woman). In the hippocampus, O157 patient 1 (82-year-old woman) was compared with control 1 (
O157 patient 2 (88-year-old woman) and O157 patient 3 (90-year-old woman) were compared with control 2 (89
year-old woman) was compared with control 2 (89-year-old woman). Original magnification for H&E and GFAP: 
400, scale bars: 25 mm.
106 Molecular Therapy Vol. 28 No 1 January 2020Active caspase-3, an indicator of apoptosis, was
evaluated in the E32511-infected NOD-SCID
mouse brain. Active caspase-3 was detected at
significantly higher rates in the medulla oblon-
gata and pons in the non-Muse group than in
the Muse group (p < 0.05; Figure S2D).
GFAP Staining in the Brain of a STEC-
Infected Patient
Figures 4A and 4B show a case control (43-year-
old man) and an autopsy case of a 43-year-oldwoman infected by O111, respectively. In the O111-infected brain, as-
trocytes detected by anti-GFAP were observed in the cerebrum with
particularly strong reactivity around the vessels and in microvascular
lesions (Figure 4B, P1, 1,2,3, GFAP). The reactive astrocytes became
clasmatodendritic (Figure 4B, P2, 4, GFAP) with a complete loss of
morphology and vacuolar degeneration in the thalamus (Figure 4B,ation of human brain sagittal sections usingMRI. The basal
ulla oblongata in the yellow box, and cerebellum in the gray
tient 3 (90-year-old woman) was compared with control 2
80-year-old woman). In the pons and medulla oblongata,
-year-old woman). In the cerebellum, O157 patient 3 (90-
100, scale bars: 100 mm; original magnification for GFAP,
Figure 6. Effects of Muse Cells on Stx2a/LPS-
Treated Reactive Astrocytes In Vitro
(A) May-Grunwald-Giemsa staining of control and Stx2a/
LPS-treated reactive astrocytes (rASTs) induced by Shiga
toxin 2 (Stx2a) and lipopolysaccharides (LPSs). Scale bars:
50 mm. (B) Images of Stx2a/LPS-treated astrocytes in (A)
were analyzed with ImageJ software to calculate the cell
area. The threshold for Stx2a/LPS-treated reactive ASTs
was set four times larger than that of control astrocytes. (C
and D) Stx2a dose response in total astrocytes (green bar)
and Stx2a/LPS-treated reactive ASTs (red bar) treated
with (C) 0 or (D) 1 mg/ml LPS for 12 h. (E) Stx2a (10 ng/mL)
increased the total number of astrocytes and Stx2a/LPS-
treated reactive ASTs in a time-dependent manner. Simi-
larly, Stx2a dose and time responses were observed (red
bar) by western blot assay. (F) GFAP+ astrocytes treated
with Stx2a (10 ng/mL) and/or LPS (1 mg/mL). The graph
shows that Stx2a (10 ng/mL) plus LPS (1 mg/mL) induced
significant upregulation of GFAP in astrocytes at 12 h after
incubation compared with Stx2a or LPS alone. **p < 0.01.
(G) Co-culture of GFP-labeled Muse or non-Muse cells
(both green cells) and Stx2a/LPS-induced reactive ASTs
(red cells; 6 h after addition of Stx2a and LPS). Significantly
more Muse cells than non-Muse cells adhered to the
culture dish after 6 h. *p < 0.05. Co-culture of GFP-labeled
Muse cells and Stx2a/LPS-reactive astrocytes for 12 h
induceda substantial decrease in reactiveASTs. *p<0.05.
Scale bars: 50 mm (inset).
www.moleculartherapy.orgP2, 4, H&E-stained sections). Clasmatodendritic was also observed in
the cerebral white matter (Figure 4B, P3, 6, GFAP).
The brains of three autopsy cases from a STEC O157:H7 outbreak
(82-, 88-, and 90-year-old females) were compared with those from
normal age-matched control brains (80- and 89-year-old females).
As shown in Figure 4C, more reactive astrocytes were detected in
the basal ganglia, hippocampus, pons, medulla oblongata, and cere-
bellum of the infected samples compared with the normal tissues.
Similarly, reactive astrocytes were observed in the brain and upper
spinal cord of O111- and E32511-infected NOD-SCID mice at 96 h
after inoculation. This time point was selected because all of theMoleinoculated mice died within 108 h (Figure S1C).
Intense GFAP immunoreactivity, suggestive of
reactive astrocytes, was identified in the medulla
oblongata of O111-infected NOD-SCID mice
and in the pons and spinal cord of E32511-in-
fected mice (Figure S4).
Engraftment of Intravenously InjectedMuse
Cells into O111-Infected NOD-SCID Mouse
Brain Suppressed Reactive Astrogliosis
We next assessed the effectiveness of intrave-
nous injection of human Muse cells into
NOD-SCID mice infected with O111. Theschema of experiments is shown in Figures 5A and 5B. Mice were
orally inoculated with O111 and intravenously injected with 5 
104 human Muse/non-Muse cells at either 24 or 48 h after inocula-
tion. Mice were killed the day after the injection, and the whole brain
was cut into sagittal sections for immunohistochemistry. Human
COX IV+-Muse cells were identified in the reticular formation of
the medulla oblongata in both the 24- and 48-h groups (Figure 5B,
B-4). Total area (green bars) and number of engrafted cells (blue
bars) were higher in mice injected with Muse cells than in those in-
jected with non-Muse cells, at both 24 and 48 h (Figure 5B, green
and blue colored graph). The total area (yellow bars) and number
(red bars) of GFAP-positive cells did not differ between the Muse
and non-Muse groups at 24 h, but at 48 h, the Muse group had fewercular Therapy Vol. 28 No 1 January 2020 107
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colored graph). These findings suggested that Muse cells injected
intravenously 48 h after O111 infection engrafted to the encephalitic
brain and rapidly suppressed reactive astrocytes. A similar tendency
was observed in coronal brain sections of mice inoculated with
E32511 (Figure S5).
Effects of Muse Cells on Stx2a/LPS-Treated Astrocytes In Vitro
May-Grunwald-Giemsa staining revealed that reactive astrocytes
treated with Stx2a/LPS have amore diffuse cytoplasm than non-treated
astrocytes (control), as shown in Figure 6A. Therefore, in this experi-
ment, the criterion for Stx2a/LPS-treated reactive astrocytes was a
4-fold larger size than control astrocytes (Figure 6B). There was no dif-
ference in detected reactive astrocyte between the 4-fold larger sized
astrocytes and GFAP immunostaining reactive astrocytes (Figure S6).
In each chamber, the number of Stx2a/LPS-treated reactive astrocytes
was counted in four fields under a 40 objective, and the mean of three
samples was calculated. Combined treatment with 10 ng/mL Stx2a and
1 mg/mL LPS for 12 h significantly upregulated the number of GFAP+
reactive astrocytes, as confirmed by western blot (Figures 6C–6E).
Immunohistochemical analysis revealed that combined treatment
with 10 ng/mL Stx2a and 1 mg/mL LPS for 12 h significantly upregu-
lated the number of GFAP+ astrocytes compared with treatment
with either Stx2a or LPS alone (Figure 6F). In addition, treatment
with either Stx2a or LPS alone increased the number of GFAP+ reactive
astrocytes, but the number was not as high as when treated with the
combination of Stx2a and LPS (Figure 6F). To assess the effect of
Muse and non-Muse cells, astrocytes were cultured overnight in astro-
cyte basal medium, and then GFP-labeled Muse or non-Muse cells
were added to astrocytes with 10 ng/mL Stx2a and 1 mg/mL LPS for
co-culture. A greater number of Muse cells attached to the culture
dish compared with non-Muse cells at 6 h (Figure 6G), and a smaller
number of GFAP+ astrocytes was observed in the Muse cell co-culture
compared with the non-Muse cell co-culture in the presence of Stx2a
and LPS at 12h (Figure 6G). These findings suggested that reactive as-
trocytes were more effectively suppressed by Muse cells than by non-
Muse cells.
Microarray Analysis of Human Muse and Non-Muse Cells
We performed microarray analysis to assess the effect of Muse/non-
Muse cells on Stx2a/LPS-treated reactive astrocytes (Figure 7A). The
microarray analysis was repeated twice. We evaluated the expression
of approximately 1,000 of 49,178 probes. To identify upregulated or
downregulated genes between control and experimental samples, we
calculated the Z score [Z] and ratio (non-log-scaled fold change)
from the normalized signal intensities of each probe, and established
criteria for regulated genes: Z scoreR 2.0 and ratioR 1.5-fold (up-
regulated genes), and Z score%2.0 and ratio% 0.66-fold (down-Figure 7. Microarray Analysis
(A) Protocol for microarray analysis. (B) Pathway determination by ingenuity pathway an
number of the protocol). (C) The heatmap data of comparison 1. (D) Results of digital PC
astrocytes either with or without co-culture with Muse and non-Muse cells. NT; no tesregulated genes) (the ratio of Muse and non-Muse cells at 6 h [Table
S1] and 12 h [Table S2] after adding Stx2a and LPS). In the detailed
microarray protocol (Figure 7A, the colored rightmost number),
comparison 1, comparison 2, comparison 3, and comparison 4 indi-
cated a ratio of 6h_M1 to 6h_n1, 6h_M1 to 6h_n2, 6h_M2 to 6h_n1,
and 6h_M2 to 6h_n2, respectively (Table S1). Comparison 5, com-
parison 6, comparison 7, and comparison 8 indicated a ratio of
12h_M1 to 12h_n1, 12h_M1 to 12h_n2, 12h_M2 to 12h_n1, and
12h_M2 to 12h_n2, respectively (Table S2). Genes focused on the
keyword “neuronal differentiation” were predominantly identified
through ingenuity pathway analysis (IPA). In particular, the granu-
locyte-colony-stimulating factor (G-CSF) gene was significantly up-
regulated more than 14.5-fold in response to Stx2a/LPS treatment
(Figure 7B; comparison 1 in Table S1). Fibroblast growth factor-
20, insulin-like growth factor-2, and other genes were reduced
approximately 10-fold in the presence of reactive astrocytes
(Figure 7B; comparison 1 in Table S1). The heatmap is shown in
Figure 7C and in comparison 1 in Table S1. The microarray results
were verified by digital PCR analyses with TaqMan gene expression
assays using eukaryotic 18S rRNA as an endogenous control. Signif-
icantly increased G-CSF mRNA expression was detected in Muse
cells co-cultured with Stx2a/LPS-treated reactive astrocytes for
12 h compared with non-Muse cells cultured in the same manner
(p < 0.05; Figure 7D).
Muse Cell Rescue Effects in O111-Infected NOD-SCID Mice Are
Mediated in Part by G-CSF
To clarify the role of G-CSF in the Muse cell effects, we introduced G-
CSF (identical to colony stimulation factor 3 [CSF3])-small interfer-
ence RNA (siRNA) into Muse cells that were then intravenously in-
jected into O111-infected NOD-SCID mice. We first developed a
100% surviving NOD-SCID mouse model by orally inoculating
O111 at a dose of 9  109 CFU, and then 5  104 Muse cells were
intravenously administered at 48 h after infection (Figure 8A). All
NOD-SCID mice (100%) with intravenous administration of 5 
104 Muse cells survived for more than 2 weeks after O111 infection
(Figure 8B). The survival rate in the control group injected with
PBS was significantly reduced at 2 weeks (43%, p < 0.05; Figure 8B).
Nonetheless, the body weights of mice in the control group were not
significantly lower than those of mice in the Muse group from 48 to
132 h (Figure 8C).
Next, we used three kinds of siRNA to interfere with the G-CSF
expression (Silencer Select Thermo Fisher Scientific Ink siRNA:
s3606, s3607, and s3608). Compared with Muse cells transfected
with non-targeting control-siRNA (NC-siRNA), siRNA s3607
reduced G-CSF transcript levels by 51% in Muse cells, which was
the highest suppression rate among the three siRNAs (Figure S7A).alysis of microarray data in comparison 1 (6h_M1 to 6h_n1 in the colored rightmost
R analyses with TaqMan gene expression assays for G-CSF expression in reactive
ted, ns; not significant. **p < 0.01.
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Figure 8. G-CSF siRNA Abolished the Increased Survival Effect of Muse Cells in O111-Infected NOD-SCID Mice
(A) Experimental protocol. (B) The O111-infected NOD/SCID mice showed 100% survival (red line). The control group received an intravenous injection of PBS in the same
volume as the Muse group (black line). (C) Change in body weight in the Muse and control groups after O111 infection. Statistical analysis was performed by the log rank test
(legend continued on next page)
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in Muse cells to 21% that of controls (Figure S7B). We then investi-
gated the effect of G-CSF suppression on the survival rate and change
in body weight. Notably, 40% ofmice treated with G-CSF siRNA-con-
taining Muse cells died and 60% survived. None of the mice treated
with NC-siRNA Muse cells died within 2 weeks (Figure 8D). Body
weight was significantly reduced from 60 to 96 h in mice treated
with CSF3-siRNA-transfected Muse cells compared with mice treated
with NC-siRNA-transfected Muse cells (Figure 8E). These findings
suggested that G-CSF contributes to the survival effect of Muse cells
in O111-infected NOD-SCID mice.DISCUSSION
The beneficial effects of Muse cells on STEC-associated acute enceph-
alopathy were demonstrated by several key findings. First, intrave-
nous administration of only 5  104 human Muse cells effectively
prolonged survival of mice infected with a lethal dose of STEC
(1  1010 CFU of O111 or E32511). Second, some mice in the
Muse group survived for up to 3 months. Histologic analysis of these
mice revealed the integration of intravenously administered human
Muse cells having a neuron-like morphology in the brain. Third,
Muse cell injection decreased the number of GFAP+ reactive astro-
cytes and suppressed caspase-3 activation in the brain. Muse cells
have been applied to clinical trials for acute myocardial infarction,
stroke, epidermolysis bullosa, and spinal cord injury by intravenous
injection of donor-derived Muse cells without HLA-matching and
immunosuppressant treatment.25 The same strategy is expected to
be successful for emergency treatment of STEC-associated acute en-
cephalopathy (Figure 8F).
Reports of human autopsy cases obtained during the outbreak of STEC
O111 in Japan indicated a relationship between reactive astrocytes and
brain edema and hernia induced by Stx2a-producing STEC O111:H8,
which was believed to be the cause of death.32 In this study, we
confirmed the presence of reactive astrocytes in autopsy cases of
STEC-infected patients. Thus, controlling reactive astrocytes is a
critical goal in treating STEC-associated acute encephalopathy. O111-
and E32511-infected NOD-SCID mice also exhibited reactive astro-
cytes in the medulla oblongata, pons, and upper spinal cord. In a previ-
ous study, we demonstrated high-intensity areas in the reticular forma-
tion of the medulla oblongata in the O111-infectedmouse model using
in situ hybridization,12 consistent with another study reporting the
same finding by MRI in a rabbit model of Stx2a toxicity, suggesting
that STEC infection affects the medulla oblongata.33 In the present
study, we detected Muse cells in this area, but very few non-Muse cells,
andmice treatedwithMuse cells exhibited reduced caspase 3-positivity.(Mantel-Cox) for survival curves or post hoc tests (Scheffe’s and Tukey’s) for the chang
introducedMuse cells (green line) andNC (Control)-siRNA-introducedMuse cells (red line
in body weight after intravenous administration of G-CSF-siRNA-Muse cells (green line)
tests (Scheffe’s and Tukey’s). (F) Schematic of Muse cell treatment. Patients with S
intravenous injection without HLA matching and long-term immunosuppressant use. M
mation, immunomodulation, anti-apoptosis, G-CSF production, protection effect, andSteroid pulse therapy might have a protective effect against BBB
impairment induced by Stx2a. Importantly, however, b-methasone
sodium phosphate-steroid pulse therapy has limited protective effects
against brain edema induced by intravenous injection of Stx1a.34
Glucocorticoid dexamethasone protects neurons and decreases astro-
gliosis in mice administered a sublethal dose of Stx2a or Stx2a plus
LPS.12,35 Stxs have N-glycosidase activity that depurates ribosomes
and stops protein synthesis in the translation elongation phase.8
The resulting ribotoxic stress response leads to activation of the p38
mitogen-activated protein kinase pathway36 and the expression of cy-
tokines such as interleukin-1b and interleukin-8 in macrophage-like
cells.37 Boccoli et al.15 reported that intracerebroventricular adminis-
tration of Stx2a increases astrogliosis in rats. In the brain, aquaporin-4
(AQP4) is localized to the perivascular endfeet of astrocytes, and an
increase in GFAP immunoreactivity in peri-vasculature astrocytes
is associated with downregulation of AQP4 expression in rats injected
with culture supernatants of E. coli-expressing Stx2a.38 A sublethal
dose of Stx2a causes BBB disruption and astrocytic edema in
mice.39 BBB impairment accompanied by a downregulation of
AQP4 expression is associated with reactive astrogliosis induced by
Stx2a.38 In the present study, Muse cells decreased the number of
reactive astrocytes in vivo and in vitro, thereby contributing to protect
and maintain BBB integrity. A recent study showed that neuroinflam-
mation and ischemia induce two different types of reactive astrocytes,
A1 and A2. Liddelow et al.40 reported that activated microglia induce
A1 astrocytes and kill axotomized neurons by becoming neurotoxic.
On the other hand, reactive astrocytes with strong GFAP immunore-
activity were observed even without active microglia in the reticular
formation of the medulla oblongata, and neurons around reactive as-
trocytes appeared to be degenerating with vacuolar changes.12 It is
unclear whether or not the E32511-induced reactive astrocytes in
our study were A1 astrocytes.
Neurologic impairment, the most life-threatening acute complication
of STEC infection, develops in approximately 20%–25% of patients
with STEC-induced HUS and may lead to sudden death or severe
neurologic complications, including lethargy, apnea, coma, seizures,
cortical blindness, and hemiparesis.41 We previously reported that
sudden death associated with fatal encephalopathy after HUS is
significantly associated with bloody diarrhea, a complete bedridden
status, and a high white blood cell count.42 Even HUS-induced en-
cephalopathy patients who escape sudden death, however, may still
suffer the after-effects of infection, i.e., a low IQ, behavioral diffi-
culties, low verbal abilities, and lower academic achievement, partic-
ularly in children.43 Following the German outbreak of STEC O104,
severe neurologic complications, including delirium, myoclonus,
aphasia, seizure, coma, and respiratory failure, were reported in adulte in body weight. (D) Survival rate following intravenous injection of G-CSF-siRNA-
). Statistical analysis was performed using the log rank test (Mantel-Cox). (E) Change
and NC-siRNA-Muse cells (red line). Statistical analysis was performed by post hoc
TEC-associated encephalopathy were treated with donor-derived Muse cells by
use cells that homed into the brain exert pleiotropic effects including anti-inflam-
cell replacement to rescue patients. *p < 0.05. ns, not significant.
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paresis, epilepsy, seizure, aphasia, and visual disturbances.44 A range
of treatments have undergone clinical trials, including IgG immu-
noadsorption,45 plasma exchange, and the monoclonal antibody
against complement 5 (C5) eculizumab. In the present study, valida-
tion of these treatments was not performed because NOD-SCIDmice
have no IgG or complement activity. We found that a single injection
of as few as 5 104 Muse cells at 48 h after O111 infection had bene-
ficial effects and prolonged survival of mice with fatal encephalopathy
without the associated neuronal damage, including spinal deformity
and paralysis. Future studies are needed to optimize the Muse cell
dosage.
Stxs-induced N-glycosidase activity inhibits protein synthesis,8 but it
is unknown whether Stx-induced apoptosis or necrosis of cells occurs
after binding to the surface of Gb3. Stx1-induced apoptosis in HeLa
cells within 4 h requires the presence of caspase-6, -8, and -9, followed
by activation of caspase-3, leading to nuclear DNA fragmentation.46
The initial cause of the apoptotic pathway induction, however, re-
mains unknown.We focused on the ER stress response, a well-known
trigger of apoptosis, and clarified that protein kinase R-like ER kinase,
eukaryotic initiation factor-2a, and activated transcription factor-6
signaling pathways play an essential role in the expression of C/
EBP homologous protein, a cellular stress sensor, during ER stress.47
Stx2a-induced apoptosis is mediated by ER stress involving C/EBP
homologous protein in human brain microvascular endothelial cells,
which leads to apoptosis mediated through intrinsic and extrinsic
apoptosis pathways.48 Using microarray analysis, we identified G-
CSF as an important factor in the effect of Muse cells on O111-asso-
ciated mouse acute encephalopathy. G-CSF is a 19.6-kDa glycopro-
tein used for the treatment of neutropenia.49 It is a hematopoietic
growth factor produced by monocytes, mesothelial cells, fibroblasts,
and neurons that promotes the survival of mature neutrophils.50 G-
CSF treatment is associated with significant improvement of the left
ventricular ejection fraction in patients with acute myocardial infarc-
tion51 and effectively suppresses ER stress in a model of middle cere-
bral artery occlusion.52 Notably, knockdown of G-CSF in Muse cells
attenuated their effects on survival in O111-infected mice. Body
weight was also significantly reduced in mice treated with the G-
CSF knockdown Muse cells. Furthermore, in the 100% surviving
NOD-SCID mouse model established by oral inoculation of O111,
intravenous administration of 5  104 Muse cells at 48 h after infec-
tion led to 100% survival compared with 43% survival of the control
group injected with PBS. The effect of Muse cells may be partially
mediated by G-CSF production, which maintains AQP4 integrity
and vascular endothelial growth factor induction, leading to
improved neurologic functions by reducing brain edema, BBB perme-
ability, neuronal death, and apoptosis.53 G-CSF also stimulates prolif-
eration of neuronal/glial progenitor cells, improves neurocognitive
function, and restores cerebral white matter damage from irradiation
injury.54
This study has some limitations. The use of NOD-SCIDmice allowed
the use of humanMuse cells to distinguish exogenousMuse cells from112 Molecular Therapy Vol. 28 No 1 January 2020endogenous Muse cells, but limits this study to evaluating the ability
of Muse cells to protect against STEC in immunodeficient mice.
Future studies using mouse Muse cells in immunocompetent mice
should be performed. In addition, the study examined a limited num-
ber of doses of Muse cells at only two time points. Further studies to
determine the optimal dosing should be performed. Lastly, small
numbers of mice were used for the survival analyses. Larger numbers
would allow for analysis of the dose that kills 50% of the mice and
more quantitative analysis.
Many STEC patients with severe neuronal complications develop
epilepsy and intellectual disability. The anti-inflammatory and anti-
apoptotic effects of Muse cells may synergistically increase the prob-
ability of a good outcome for patients with neurologic involvement
associated with STEC infection. Further in vitro and in vivo studies
are required to clarify the mechanisms underlying the survival effects
of Muse cells in STEC infection.
MATERIALS AND METHODS
Ethics Statement
Animal experiments were carried out in strict accordance with the
recommendations in the Guidelines for the Proper Conduct of
Animal Experiments formulated by the Science Council of Japan.
The protocol was approved by the Committee on the Ethics of Animal
Experiments of Kyushu University (Permit Number: A23-141-1) and
Tottori University (Permit Number: 14-Y-17). All surgeries were per-
formed under sevoflurane anesthesia, and all efforts were made to
minimize suffering.
Animals
Female ICR and NOD-SCID mice (14–18 g) were purchased from
Charles River Laboratories Japan (Yokohama, Japan). NOD-SCID
mice are characterized by an absence of functional T and B cells, lym-
phopenia, hypogammaglobulinemia, normal antigen-presenting cells,
myeloid cells, and natural killer cells. The mice also have no detectable
IgM, IgG1, IgG2a, IgG2b, or IgG3. Therefore, NOD-SCID mice
(https://www.jax.org/strain/001303) could accept human Muse or
non-Muse cells for cell transfer experiments in contrast with using
nude mice. Mice were housed in cages with a 12-h light-dark cycle
and were provided with free access to food and distilled water.
Bacterial Strains and Streptomycin- and Mitomycin C-Resistant
STEC
We used the clinically isolated strain of Stx2-producing STEC
O111:H8 (STEC O111) from the Toyama prefecture outbreak. The
Stx2c-producing E. coli O157:H- strain E32511/HSC (STEC O157)
was a kind gift from Prof. Mohamed A. Karmali (McGill University,
Québec, Canada). The Stx1- and Stx2-producing STEC O157 strain
Tokyo-EH5487 (STEC O157 Tokyo) associated with the cucumber
outbreak in Chiba and Tokyo in 2016 was obtained from the Depart-
ment of Food Microbiology at the Tokyo Metropolitan Institute of
Public Health. Stx1- and Stx2-producing STEC O157:H7 strain Sakai
(STEC O157 Sakai) (RIMD 0509939) was purchased from the
Pathogenic Microbes Repository Unit of Osaka University. To obtain
www.moleculartherapy.orgbacteria resistant to streptomycin (SM) and mitomycin C (MMC),
STEC were grown in nutrient agar supplemented with 100 mg/mL
SM (Wako Pure Chemical Industries, Osaka, Japan) and 0.5 mg/mL
MMC (Kyowa Hakko Kogyo, Tokyo, Japan).
Stx2a Purification
Stx2a was immunoaffinity purified from a clinical isolate of STEC.55
The Stx2a was determined to be free of detectable LPS by the Toxi-
color test, SDS-PAGE, and silver staining.
Preparation of Muse and Non-Muse Cells
Muse and non-Muse cells were prepared from adult human BM-MSCs
(Lonza, MD, USA) as described previously.26 Non-Muse cells and cells
other thanMuse cells in BM-MSCs are hereafter referred to as SSEA-3
cells. SSEA-3+ (Muse cells) and SSEA-3 (non-Muse cells) were sepa-
rated according to previous reports.26 To prepare GFP-labeled Muse
andnon-Muse cells, BM-MSCswere infectedwith a lentivirus encoding
GFPat an efficiencyof70%asdescribedpreviously.26GFP-expressing
BM-MSCswere separated by positive expression of SSEA-3. GFP-Muse
cells were double-positive for GFP and SSEA-3, whereas GFP-non-
Muse cells were positive for GFP but negative for SSEA-3. The use of
these cells was not in conflict with any regulations of our university.
STECOrally InfectedMouseModels andMuse or Non-MuseCell
Injections
A mouse model was established with STEC inoculated orally and
MMC administered via intraperitoneal (i.p.) injection according to
the previous report.11 In brief, all mice were provided with SM-con-
taining drinking water (5 g/L) ad libitum to reduce normal intestinal
flora. On day 3 of SM treatment, mice were deprived of food for 12 h
until bacterial inoculation in order to avoid absorption of inoculated
STECs by food or preventing disturbance of STEC colonization by
food.11,56 Each mouse was orogastrically inoculated with 0.5 mL of
a bacterial suspension using a syringe attached to a sterile disposable
feeding needle (diameter, 1.9 mm; length, 38 mm; Fuchigami, Nara,
Japan) passed into the stomach. Simultaneously, they were injected
i.p. with 2.5 mg/g MMC. In this study, bacterial suspensions of
EHEC O111 and EHEC O157 (E32511) strains (hereafter referred
to as E32511), the Stx1- and Stx2-producing STEC O157 strain
Tokyo-EH5487 (hereafter referred to as STEC O157 Tokyo), and
the Stx1- and Stx2-producing STEC O157:H7 strain Sakai (hereafter
referred to as STEC O157 Sakai) were adjusted to the appropriate
CFU in PBS. After treatment, mice were returned to their respective
housing and given food and SM-containing drinking water (5 g/L) ad
libitum. Mice were observed every 12 h for survival and signs of
illness, and body weight measurements were performed. To avoid
technical errors associated with oral STEC inoculation, mice were
inoculated with E. coli K-12 (SMr and MMCr) and survived (100%)
(data not shown). Therefore, in this study, technical errors were not
described in the Results.
Bioluminescence Imaging
Bioluminescence imaging with an IVIS was conducted as described
previously.57 In brief, eight mice were infected with 1  1010 CFUSTEC E32511 or O111 (four mice for each strain). After 1 or
2 days, mice were intravenously injected with nano-lantern-labeled
Muse or non-Muse cells (1  105/mouse).25 Mice were then intrave-
nously injected with 100 mL substrate (80 mg/mL coelenterazine-h;
Wako, Tokyo, Japan), anesthetized with isoflurane by inhalation,
and placed in an acrylic plastic box. Bioluminescent images were ac-
quired using an IVIS (Spectrum; PerkinElmer, Waltham, MA, USA)
using the following settings: exposure time, 1 min; medium binning,
F/Stop = 1. Data acquisition and analysis were performed
using Living Image 4.4 software (PerkinElmer). Quantification was
performed using a region of interest (ROI) definedmanually (abdom-
inal center or injection site), and the results are expressed as photons
per second (P/s).
Immunohistochemistry with Tyramide Signal Amplification
Immunohistochemistry with tyramide signal amplification
(mIHC) was performed as described by the protocol from Cell
Signaling Technology (https://en.cellsignal.jp/contents/resources-
protocols/fluorescent-multiplex-immunohistochemistry-(mihc)-with-
tyramide-signal-amplification-protocol/fluorescent-multiplex-ihc-w-
tyramide). In brief, paraffin-embedded mouse brain tissues were
deparaffinized with xylene and then rehydrated with 100%
ethanol, 95% ethanol, and dH2O. For antigenic unmasking, tissue
sections were boiled in sodium citrate buffer (pH 6.0) in a micro-
wave. Sections were quenched by incubation in 3% hydrogen
peroxide for 10 min. Anti-mouse CD31, anti-mouse b3-tubulin,
and anti-COX IV rabbit monoclonal antibodies were purchased
from Cell Signaling Technology (Danvers, MA, USA). A ready-
to-use anti-GFAP rabbit polyclonal antibody (Dako) was also
used as a primary antibody. Primary antibodies were diluted in
SignalStain Antibody Diluent (Cell Signaling Technology), and
sections were incubated under humidified conditions at room tem-
perature. Subsequent incubations with SignalStain Boost IHC
Detection Reagent (rabbit-horseradish peroxidase [HRP]; Cell
Signaling Technology) were performed in a humidified chamber.
Tyramide signal amplification (TSA) was performed using the
TSA Plus Cyanine 3/Fluorescein System (PerkinElmer, Waltham,
MA, USA), according to the manufacturer’s recommendations.
Sections were incubated in tyramide-fluorophore conjugate and
amplification reagent for 10 min at room temperature in a humid-
ified chamber while protected from light. For double staining,
sections were first stripped by boiling in sodium citrate buffer
(pH 6.0) in a microwave and then stained using a different tyra-
mide-fluorophore conjugate. Three rounds of double staining
were performed using the TSA Plus Cyanine 3/Fluorescein System.
Cells were stained with an anti-COX IV rabbit monoclonal anti-
body (1:1,000; Cell Signaling Technology) counterstained with
cyanine 3 (Thermo Fisher Scientific, Invitrogen) along with one
of the following antibodies (all counterstained with fluorescein):
(1) anti-CD31 (1:800; Cell Signaling Technology), (2) diluted
ready-to-use anti-GFAP (1:10; Dako), or (3) anti-b3-tubulin
(1:2,000; Cell Signaling Technology). All sections were mounted
with coverslips using ProLong Gold Antifade Reagent with DAPI
(Cell Signaling Technology). Specimens were examined underMolecular Therapy Vol. 28 No 1 January 2020 113
Molecular Therapythe BZ-X700 HS All-in-One Fluorescence Microscope and a
LSM780 confocal microscope (ZEISS Research, Japan). Using
ZEN version 2.3 (blue edition) software of the confocal micro-
scope, we made three dimensional (3D) images.
Forensic Autopsies in the Outbreak of STEC O111 and O157
Infections in Japan
Human brain tissues were obtained from forensic autopsies of three
individuals. Paraffin-embedded brain sections were obtained from a
43-year-old woman with brain edema and hernia, who subsequently
died of STEC infection in the Toyama prefecture during an outbreak
of Stx2-producing STEC O111 and O157 infections that occurred in
Japan in 2011. The autopsy was performed at the Department of Legal
Medicine, Graduate School of Medicine and Pharmaceutical Sciences,
University of Toyama. Control paraffin-embedded brain sections
from a 43-year-old male were provided by the Division of Neuropa-
thology, Tottori University. In addition, paraffin-embedded brain
sections without any brain lesions were provided for three females
(82, 88, and 90 years of age), who died in the Tokyo outbreak of
2016 from STEC O157:H7 caused by cucumbers. Their autopsies
were performed at the Department of Forensic Medicine, Jikei Uni-
versity School of Medicine. Age- and sex-adjusted control samples
(80- and 89-year-old females) were provided by the Division of Legal
Medicine, Department of Social Medicine, Faculty of Medicine,
Tottori University. All human autopsy and control brain sections
were stained with H&E and GFAP immunohistochemistry. All pro-
cedures were performed in accordance with the guidelines of the
Japanese Society of Legal Medicine.
Immunohistochemistry of Paraffin-Embedded Sections
Mice were anesthetized with sevoflurane (Maruishi Pharmaceutical,
Osaka, Japan). Then, the mice were perfused using a Perista pump
(SJ-1211II-H; ATTO, Japan) from the left ventricle with 10 mL PBS
and 40 mL of 4% paraformaldehyde (PFA; Wako Laboratory Chem-
icals, Osaka, Japan) in PBS for fixation. The brain and spinal cord
were harvested and fixed in 4% PFA in PBS. The brain was then pro-
cessed for immunohistochemical examination. Formalin-fixed,
paraffin-embedded tissue blocks were cut into 6-mm-thick sections.
For immunohistochemistry (IHC), tissue sections were deparaffi-
nized with xylene and rehydrated through an ethanol series and
Tris-buffered saline (TBS). Antigen retrieval was performed by
enzyme treatment with Proteinase K (Takara Bio, Shiga, Japan).
Endogenous peroxidase activity was blocked with 0.3% H2O2 in
methanol for 30 min, followed by incubation with Protein Block
(Genostaff, Tokyo, Japan). Sections were incubated with undiluted
rabbit polyclonal antibody against GFAP (1 mg/mL; Dako Denmark,
Glostrup, Denmark) at 4C overnight and then with EnVision+ Sin-
gle Reagent (Dako) for 30 min at room temperature. Peroxidase activ-
ity was visualized by diaminobenzidine. Alternatively, sections were
incubated with an anti-human COX IV rabbit monoclonal antibody
(1:2,000; Cell Signaling Technology, Beverly, MA, USA) at 4C over-
night, followed by biotin-conjugated goat anti-rabbit Ig (1:600; Agi-
lent Dako Technologies) for 30 min at room temperature. Sections
were then incubated with peroxidase-conjugated streptavidin (Ni-114 Molecular Therapy Vol. 28 No 1 January 2020chirei, Tokyo, Japan) for 5 min. All sections were counterstained
with Mayer’s hematoxylin (MUTO Pure Chemicals, Tokyo, Japan),
dehydrated, and then mounted with Malinol (MUTO Pure Chemi-
cals). Specimens were examined using the BZ-X700 HS All-in-One
Fluorescence Microscope. The numbers and areas of Muse/non-
Muse cells or reactive astrocytes were quantified with a BZ-X
Analyzer and the color extraction mode of the Hybrid Cell Count
software (Keyence). mIHC was performed to human Muse or non-
Muse cells in O111-infected mice as described above. In brief,
paraffin-embedded mouse brain tissues were deparaffinized with
xylene and then rehydrated with 100% ethanol, 95% ethanol, and
dH2O. For antigenic unmasking, tissue sections were boiled in
sodium citrate buffer (pH 6.0) in a microwave. Sections were
quenched by incubation in 3% hydrogen peroxide for 10 min. Anti-
COX IV rabbit monoclonal antibodies were purchased from Cell
Signaling Technology (Danvers, MA, USA). Primary antibodies
were diluted in SignalStain Antibody Diluent (Cell Signaling Tech-
nology), and sections were incubated under humidified conditions
at room temperature. Subsequent incubations with SignalStain Boost
IHC Detection Reagent (rabbit-HRP; Cell Signaling Technology)
were performed in a humidified chamber. Tyramide signal amplifica-
tion (TSA) was performed using the TSA Plus Cyanine 3/Fluorescein
System (PerkinElmer, Waltham, MA, USA), according to the
manufacturer’s recommendations. Sections were incubated in tyra-
mide-fluorophore conjugate and amplification reagent for 10 min
at room temperature in a humidified chamber while protected from
light. For the staining of Muse or non-Muse cells, sections were first
stripped by boiling in sodium citrate buffer (pH 6.0) in a microwave
and then stained using a tyramide-fluorophore conjugate. The stain-
ing was performed using the TSA Plus Cyanine 3/Fluorescein System.
Cells were stained with an anti-COX IV rabbit monoclonal antibody
(1:1,000; Cell Signaling Technology) counterstained with cyanine 3
(Thermo Fisher Scientific, Invitrogen). The sections were mounted
with coverslips. Specimens were examined under the BZ-X700 HS
All-in-One Fluorescence Microscope to count the total area that
contained Muse cells and the number of engrafted Muse cells with
BZ-X analyzer.
May-Grunwald-Giemsa Staining and Western Blot Assay
Mouse C57 mixed astrocytes (astrocytes) (M-AsM-330; Lonza,
Walkersville, MD, USA) were maintained in ABM astrocyte basal
medium (CC-3187; Lonza). For in vitro experiments, astrocytes
were seeded in two-well Lab-Tek chamber slides with covers (Nalge
Nunc International, Roskilde, Denmark) and incubated at 37C
with 5% CO2. Stx2a- and/or LPS-treated activated astrocytes (reactive
astrocytes) were subjected to May-Grunwald-Giemsa staining using
an automated hematology slide preparation machine (SP-10; Sysmex,
Kobe, Japan). Images of normal astrocytes and reactive astrocytes
were captured using the All-in-One Microscope (Keyence) under a
40 objective, and the area was calculated using ImageJ 1.52a
(NIH, Bethesda, MD, USA). The number of reactive astrocytes was
counted in four fields for each chamber slide, and the mean of three
samples was calculated. The area of reactive astrocytes was more than
4-fold that of control astrocytes. To observe reactive astrocytes in a
www.moleculartherapy.orgdose- and time-dependent manner, reactive astrocytes were lysed and
subjected to western blot assay. Protein expression was quantified us-
ing the Lumino Image Analyzer LAS1000 plus (FUJIFILM, Tokyo,
Japan). The hallmark of astrocyte activation is enhanced expression
of the major intermediate filament protein GFAP that was detected
by western blot assay using an anti-mouse GFAP rabbit antibody
(Dako) and HRP-conjugated antibody (Sigma-Aldrich, St. Louis,
MO, USA) as described previously by Bitko and Barik.58 Immunode-
tection was carried out using the ECL detection system (Amersham
Pharmacia Biotech, UK).
GFP Labeling of Muse and Non-Muse Cells
Human BM-mesenchymal stem cells (MSCs) (Lonza) were infected
with a lentivirus encoding GFP, and Muse cells were collected as
SSEA3+ cells. For immunofluorescence staining, mouse astrocytes
and Muse/non-Muse cells (10,000 cells each) were co-cultured over-
night in two-well chamber slides (Nalge Nunc International). The
next day, the medium was discarded and several concentrations of
Stx2 and 1 mg/mL purified LPS derived from E. coli O55:B5
(Sigma-Aldrich) were used to induce reactive astrocytes. After 6 or
12 h, cells were fixed with 4% PFA for 30 min and then washed twice
with PBS. Cells were blocked with blocking buffer (5% normal goat
serum/0.3% Triton X-100 in PBS) for 1 h at room temperature and
immunostained overnight at 4C with an anti-GFAP mouse mono-
clonal antibody (Alexa Fluor 594, #8152; Cell Signaling Technology)
diluted by a factor of 100 with dilution buffer (1% BSA/0.3% Triton
X-100 in PBS). Samples were stained with DAPI, washed twice with
PBS, and mounted with SlowFade antifade solution (Invitrogen).
Specimens were examined under the BZ-X700 HS All-in-One Fluo-
rescence Microscope (Keyence, Osaka, Japan).
Microarray Analysis
First, 100,000 primary astrocytes were placed into a T75 cell culture
flask (75 cm3 for adherent cells; Nalge Nunc International) in ABM
astrocyte basal medium and incubated at 37C with 5% CO2. After
18 h, ABM was replaced with fresh ABM, along with 100,000 hu-
man non-Muse or Muse cells and 10 ng Stx2 and 1 mg/mL LPS.
At 6 or 12 h after incubation, reactive astrocytes and Muse or
non-Muse cells were detached with 0.25% trypsin (GIBCO), and
the Muse or non-Muse cells were separated from the reactive astro-
cytes using human CD105 MicroBeads (Miltenyi Biotec) and a mag-
netic separator (MiniMACS Separator; Miltenyi Biotec). Total RNA
was isolated from Muse and non-Muse cells individually using TRI-
zol Reagent (Life Technologies) and purified using the SV Total
RNA Isolation System (Promega), in accordance with the manufac-
turers’ instructions. Also, the reactive astrocytes were collected in
TRIzol Reagent and are being analyzed currently. RNA samples
were quantified by an ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA), and the quality was
confirmed with a 2200 TapeStation (Agilent Technologies, Santa
Clara, CA, USA). cRNA was amplified, labeled, and hybridized to
a 60K Agilent 60-mer oligomicroarray (Agilent Trusted Answers,
CA, USA) using the SurePrint G3 Human Gene Expression Micro-
array 8  60K v3 labeling kit (Low Input Quick Amp Labeling Kit;#5190-2305; Agilent Trusted Answers, CA, USA), in accordance
with the manufacturer’s instructions. All hybridized microarray
slides were scanned using an Agilent scanner. Relative hybridization
intensities and background hybridization values were calculated us-
ing Agilent Feature Extraction Software (9.5.1.1). Raw signal inten-
sities and Flags for each probe were calculated from hybridization
intensities (gProcessedSignal) and spot information (gIsSaturated),
according to the procedures recommended by Agilent. Flag criteria
on GeneSpring Software included: Absent (A), “Feature is not pos-
itive and significant” and “Feature is not above background”; Mar-
ginal (M), “Feature is not Uniform,” “Feature is Saturated,” “Feature
is a population outlier”; and Present (P), others. The raw signal in-
tensities of two samples were log2-transformed and normalized by
the quantile algorithm with the “preprocessCore” library package
[P] of Bioconductor software [B]. We selected probes that called
the “P” flag in at least one sample, excluding long intergenic non
coding RNA (lincRNA) probes.
Microarray and Network Analysis
IPA version 45868156 was used to identify upregulated functionally
significant genes. To this end, we required the ratio of gene scores
for Muse cells versus non-Muse cells, comparing the results at 6
and 12 h after incubation with reactive astrocytes, Stx2, and LPS. Us-
ing the IPA tool, networks were generated based on an algorithmically
generated score. The Z score was used to rank networks according to
their relevance to genes present within the dataset. Canonical path-
ways significant to the input dataset were identified from the IPA li-
brary of neuronal differentiation pathways based on two parameters,
viz.: (1) the ratio of the number of genes within the dataset mapping
to the pathway divided by the total number of genes mapping to the
neuronal differentiation pathways; and (2) the p value (calculated
based on Fischer’s exact test), which determined the probability
that each bio-function assigned to that dataset and canonical pathway
was not due to chance alone. Upstream regulators were defined as
genes that affected the expression of numerous other genes, whereas
canonical pathways were defined as the idealized or generalized path-
ways that represent common properties of a particular signalingmod-
ule or pathway.
RNA Quantification by Digital PCR
Ten thousand primary astrocytes were seeded in six-well culture
plates (Nalge Nunc International) in ABM and incubated at 37C
with 5% CO2 for 18 h. Culture medium was replenished, along with
the addition of 10,000 human non-Muse or Muse cells, and 10 ng
Stx2 and 1 mg/mL LPS. After 6 or 12 h, the cells were detached
with 0.25% trypsin (GIBCO), and the Muse and non-Muse cells
were separated from reactive astrocytes using CD105 MicroBeads.
Total RNA was extracted using the PureLink RNAMini Kit (Thermo
Fisher Scientific), according to the manufacturer’s instructions. The
RNA concentration was measured using a NanoDrop Lite Spectro-
photometer (Thermo Fisher Scientific). cDNA was synthesized using
SuperScript IV VILOTM Master Mix (Thermo Fisher Scientific), ac-
cording to the manufacturer’s instructions. Samples measured by the
QuantStudio 3D Digital PCR System (Life Technologies) were loadedMolecular Therapy Vol. 28 No 1 January 2020 115
Molecular Therapyonto chips using the QuantStudio 3D Digital PCR Chip Loader in a
mixture consisting of QuantStudio 3D digital PCR Master Mix v2
(Thermo Fisher Scientific), primers, and FAM dye-labeled MGB
probes for digital PCR of CSF3 (assay ID: Hs00783432_g1; Thermo
Fisher Scientific) or the eukaryotic 18S rRNA endogenous control
(Thermo Fisher Scientific). Chips were sealed and loaded onto a
GeneAMP PCR system 9700 (Applied Biosystems) and cycled ac-
cording to the following parameters: 96C for 10 min, followed by
39 cycles of 56C for 2 min and 98C for 30 s with a final extension
of 56C for 2 min. After cycling, the endpoint fluorescence of the par-
titions on the chips was measured by transferring the chips to
the measurement unit (v3.0). Applied Biosystems QuantStudio
3D Analysis Suite Cloud Software was used to analyze and refine
the data.RNAi of G-CSF (i.e., CSF3)
For CSF3 (accession number NM_000759.3) mRNA knockdown,
three Silencer Select predesigned siRNAs (s3606, s3607, and s6308)
and NC No. 1 were purchased from Invitrogen. Human Muse cells
(3  104) growing in six-well culture dishes were incubated for
48 h in 1mL complete medium containing a mixture of 1 mL Lipofect-
amine RNAiMax (Invitrogen) and 5 or 10 nM stealth siRNA against
human CSF3. CSF3 knockdown in human Muse cells was confirmed
by the relative expression of CSF3 mRNA.59Statistical Analysis
Survival rates were compared using Kaplan-Meier tests followed by
pairwise comparisons using the log rank (Mantel-Cox) test. Differ-
ences in weight changes were tested by general linear model repeated
measures with Scheffe’s and Tukey’s post hoc tests. Statistical differ-
ences were considered significant at p values of less than 0.05 and
0.01. All statistical analyses were conducted using IBM SPSS Statistics
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